Mitsubishi Tanabe gets Market Authorization for BindRen for treatment of Hyperphosphatemia

Mitsubishi Tanabe European subsidiary Mitsubishi  Pharma Europe limited has received Market Authorization for BindRen (colestilan) for treatment of Hyperphosphatemia in patients with Chronic Kidney disease Stage V receiving haemodialysis or peritoneal dialysis. 

In patients with chronic kidney disease phosphorus is not sufficiently excreted from the body and is thus accumulated over time leading to hyperphosphatemia. In Phase 2 / Phase 3 trials, Bindren demonstrated reduction in serum phosphorus and calcium phosphate levels. 

In Japan, the product has been marketed since 1999 under the brand name "CHOLEBINE for the treatment of hypercholestorolemia.

Enter your email address:


Delivered by FeedBurner